布地奈德缓释胶囊在哪里买比较靠谱

Budesonide extended-release capsules are a drug specifically designed to treat Crohn's disease. However, it has not yet been officially launched in some regions. However, its excellent efficacy and low side effects have won wide recognition around the world. Taking into account the urgent needs of patients, this article will explore several relatively reliable purchase methods, and provide an in-depth analysis of the clinical trial effects of budesonide sustained-release capsules in the treatment of Crohn's disease, providing valuable reference information for patients.

Budesonide Sustained-Release Capsules Reliable purchase methods

1. Transnational medical platforms: Using international medical e-commerce platforms or online pharmacies, patients can purchase from overseas formal channels on the premise of complying with relevant laws and regulations. These platforms usually cooperate with internationally renowned pharmaceutical manufacturers to provide guarantee of authenticity and convenient logistics services.

2. Overseas direct mail service: Some overseas pharmacies or medical institutions provide direct mail service. Patients can place orders directly on the official website and the medicines will be mailed directly from abroad to designated addresses in China. This method reduces the intermediate links, but you need to pay attention to choosing a reputable merchant and confirm that the medicine complies with customs import regulations.

3. International medical tourism: For qualified patients, you can consider going to countries where budesonide sustained-release capsules have been launched for short-term medical tourism and purchase the required drugs at local hospitals or pharmacies. This method not only ensures the authenticity and effectiveness of medicines, but also allows you to enjoy local medical services.

Trial effect of budesonide extended-release capsules in the treatment of Crohn's disease

Trial design: In order to comprehensively evaluate the efficacy of budesonide extended-release capsules in the treatment of Crohn's disease, researchers conducted five 8-week randomized double-blind studies, including a total of 994 patients with mild to moderate active Crohn's disease in the ileum and/or ascending colon. These patients have a wide age range, a balanced gender ratio, and are mainly white, ensuring the broad applicability of the research results.

Setting of trial results: The study uses the Crohn's Disease Activity Index (CDAI) as the main indicator to evaluate the efficacy. The CDAI score can comprehensively reflect the patient's clinical symptoms, inflammation degree, quality of life and other aspects. Clinical improvement was defined as a CDAI score less than or equal to 150 after 8 weeks of treatment. The study aims to verify whether budesonide sustained-release capsules can effectively reduce CDAI scores and thereby improve patient conditions.

Trial results: Compared with placebo and the traditional drug prednisolone, budesonide extended-release capsules showed similar efficacy in reducing CDAI scores. However, in terms of the incidence of side effects, budesonide sustained-release capsules are significantly lower than prednisolone, showing better tolerance. This result is undoubtedly good news for patients with Crohn's disease, because it means that patients can get effective treatment while reducing the discomfort and risk caused by drug side effects.